Genotyping Assay Market

The genotyping assay market is projected to reach USD 37.1 Billion by 2029 from USD 19.4 Billion in 2024, at a CAGR of 13.8% during the forecast period. The growth of this market is expected to be driven by technological advancements and the decreasing prices of DNA sequencing. The high incidence of genetic diseases has also impacted the market growth in recent years. Furthermore, genotyping has become a significant aspect in drug discovery, development and personalized medicine.

The demand for genome analysis in plants and animal livestock, a rising focus on national sequencing projects to establish links between genetics and disease, and the growing application areas of genotyping are expected to provide market opportunities. However, the high cost of equipment can affect market growth to a certain extent.

To know about the assumptions considered for the study download the pdf brochure

The major players in this market are Thermo Fisher Scientific Inc. (US), Illumina, Inc. (US), Danaher Corporation (US), QIAGEN (Netherlands), Eurofins Scientific (Luxembourg), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Merck KGAA (Germany), Agilent Technologies (US), Revvity Inc. (US), Standard Bio Tools (US), PacBio (US), GENEWIZ Inc. (US), Luminex Corporation (Diasorin Company) (US), Oxford Nanopore Technologies Plc (UK), GenScript (US), Takara Bio Inc. (Japan), New England Biolabs (US),  Promega Corporation (US), Tecan Trading AG (Switzerland), Genotypic Technology Pvt. Ltd. (India), BGI GROUP (China), Novogene Co., Ltd. (China),  Paragon Genomics, Inc. (US),  NeoGenomics Laboratories (US).

Thermo Fisher Scientific Inc. (US)

Thermo Fisher held the leading position in the genotyping assay market in 2023. The players’s top position in this market is primarily due to its vast products range, which includes genomic profiling, PCR, microarray analysis, instruments and kits & reagents. Also, the company has a quite huge hold in terms of  geographical presence which covers  North America, Europe, Latin America, the Middle East, the Asia Pacific and Africa,. To maintain its top rank in the market, the company is always determined in launching new products and partnering and collaborating with other players existent in this market.

Illumina, Inc. (US)

Illumina grabbed the second position in the genotyping market in 2023. The company has been in lead with its flagship NGS platforms in the sequencing market. Reagents such as TruSeq sample preparation kits, TruSeq SBS sequencing kits, and various other sequencing reagents are provided by the company, along with services which include whole genome sequencing, human whole exome sequencing, de novo sequencing, custom-targeted resequencing, gene expression using random-primed RNA sampling, and others. To maintain its position in the market, the player is signing numerous agreements, partnerships with small scale players and launching new and innovative products to build a strong product portfolio.

Related Reports:

Genotyping Assay Market by Product & Services (Kits, Instruments,Bioinformatics), Technology (PCR, Sequencing, Microarray), Application (Pharmacogenomics, Animal Genetics), End User (PharmaBiotech Companies, Diagnostic Labs) - Global Forecast to 2029

Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA : 1-888-600-6441
[email protected]